Seizure Semiology in Antibody-Associated Autoimmune Encephalitis

Tillman Kaaden, MD,‡ Marie Madlener, MD, Clemens Angstwurm, MD, Christian G. Bien, MD, Yuri Bogarin, MD, Kathrin Doppler, MD, Alexander Finke, MD, Stefan T. Gerner, MD, Gernot Reimann, MD, Martin Häusler, MD, Robert Handreka, MD, Kerstin Hellwig, MD, Max Kaufmann, MD, Christoph Kellinghaus, MD, Peter Koertvelyessy, MD, Andrea Kraft, MD, Jan Lewenerz, MD, Til Menge, MD, Asterios Palantoni, MD, Felix von Podewils, MD, Harald Prüss, MD, Sebastian Rauer, MD, Marius Ringelstein, MD, Kevin Rostasy, MD, Ingo Schirotzek, MD, Julia Schwabe, MD, Piotr Sokolowski, MD, Marie Suesse, MD, Kurt-Wolfram Suh, MD, Rainer Surges, MD, Simone C. Tauber, MD, Franziska Thaler, MD, Florian Then Bergh, MD, Christian Urbanek, MD, Klaus-P. Wandinger, MD, Brigitte Wildemann, MD, Sigrid Mues, MD, Uwe Zettl, MD, Frank Leypoldt, MD, Nico Melzer, MD, Christian Geis, MD, Michael Malter, MD;† Albrecht Kunze, MD;‡, and the Generate Study Group

Neurol Neuroimmunol Neuroinflamm 2022;9:e200034. doi:10.1212/NXI.000000000000200034

Abstract

Background and Objectives

To assess seizure characteristics in antibody (ab)-associated autoimmune encephalitis (ab + AE) with the 3 most prevalent abs against N-methyl-D-aspartate receptor (NMDAR), leucine-rich glioma-inactivated protein 1 (LGI1), and glutamic acid decarboxylase (GAD).

Methods

Multicenter nationwide prospective cohort study of the German Network for Research in Autoimmune Encephalitis.

Results

Three hundred twenty patients with ab + AE were eligible for analysis: 190 NMDAR+, 89 LGI1+, and 41 GAD+. Seizures were present in 113 (60%) NMDAR+, 69 (78%) LGI1+, and 26 (65%) GAD+ patients and as leading symptoms for diagnosis in 53 (28%) NMDAR+, 47 (53%) LGI1+, and 20 (49%) GAD+ patients. Bilateral tonic-clonic seizures occurred with almost equal frequency in NMDAR+ (38/51, 75%) and GAD+ (14/20, 70%) patients, while being less common in LGI1+ patients (27/59, 46%). Focal seizures occurred less frequently in NMDAR+ (67/113; 59%) than in LGI1+ (54/69, 78%) or in GAD+ patients (23/26; 88%). An aura with déjà-vu phenomenon was nearly specific in GAD+ patients (16/20, 80%). Faciobrachial
Dystonic seizures (FBDS) were uniquely observed in LGI1+ patients (17/59, 29%). Status epilepticus was reported in one-third of NMDAR+ patients, but only rarely in the 2 other groups. The occurrence of seizures was associated with higher disease severity only in NMDAR+ patients.

Discussion

Seizures are a frequent and diagnostically relevant symptom of ab + AE. Whereas NMDAR+ patients had few localizing semiological features, semiology in LGI1+ and GAD+ patients pointed toward a predominant temporal seizure onset. FBDS are pathognomonic for LGI1 + AE. Status epilepticus seems to be more frequent in NMDAR + AE.

In this study, we aimed to reveal the characteristics of seizures of patients with ab + AE from the database of the German Network for Research on Autoimmune Encephalitis (GENERATE), a nationwide prospective registry for patients with ab + AE. Specifically, we focused on the 3 most common subtypes of AE with antibodies against NMDAR, LGI1, and glutamic acid decarboxylase (GAD). We sought for (1) the proportion of patients with seizures at first presentation and their leading role for making the diagnosis, (2) specificities in seizure semiology according to the detected ab, (3) the prevalence of pathologic EEG findings, and (4) the effect of seizure occurrence on disease severity.

Methods

Patients

We conducted a multicenter nationwide cohort study analyzing registry data of the GENERATE. The study focused on consecutively included patients diagnosed with ab + AE associated with abs against NMDAR, LGI1, or GAD between 2004 and 2016 from 40 collaborating hospitals. In GAD + AE, we applied more strict inclusion criteria concerning the laboratory diagnosis because low-titer GAD abs are currently classified as low specific for an AE.9

The laboratory tests for GAD abs in serum had to meet at least 1 of the following criteria: ELISA value >1,000 IU/mL, radioimmuno precipitation assay >2,000 U/mL, positive labeling cell-based assays (>1:10), or intrathecal ab synthesis (ab index >1.5).

Data were collected at each center by local investigators gathering demographic and clinical information. To assess the severity of the disease, the local investigators provided the modified Rankin score (mRS) at disease maximum in the acute disease stage.

Glossary

ab = antibody; AE = autoimmune encephalitis; FBDS = faciobrachial dystonic seizures; GAD = glutamic acid decarboxylase; GENERATE = German Network for Research on Autoimmune Encephalitis; ILAE = International League Against Epilepsy; LGI1 = leucine-rich glioma-inactivated protein 1; mRS = modified Rankin score; NMDAR = N-methyl-d-aspartate receptor; OR = odds ratio; SE = status epilepticus.
The seizure semiology was categorized according to the current classification of the International League Against Epilepsy (ILAE). In the patient population with focal seizures, patient charts were analyzed to retrieve more detailed information about focal seizure semiology. Furthermore, we assessed EEG findings from the database. This study primarily focused on the early stage of AE (i.e., the first presentation at the corresponding center where the diagnosis of ab + AE was performed).

**Standard Protocol Approvals, Registrations, and Patient Consents**

Initial institutional review board approval was given by the ethical advisory board of the University of Luebeck, Germany, (reference number: 13–162) and consecutively by the regional ethical advisory boards of all participating centers. Written informed consent was obtained from every patient or their representative.

**Statistical Analysis**

The SPSS statistic computer package (version 25.0; IBM Corporation) was used for all statistical analyses. Categorical variables were presented as numbers (n/N) and percentages. Values were given as median and interquartile range. Group comparisons of categorical variables (e.g., sex of the patients) were hierarchically performed first with the Freeman-Halton test and subsequently between 2 groups with the Fisher exact test. The Kruskal-Wallis test and Bonferroni correction for multiple tests were used to compare metrical data between 3 or 2 groups, respectively. All tests were 2-tailed; p values < 0.05 were considered statistically significant.

**Data Availability**

Anonymized data not published within this article will be made available on reasonable request from qualified investigators.

**Results**

**Patient Characteristics**

We screened 387 patients with ab + AE (205 NMDAR+, 101 LGI1+, and 81 GAD+) from the GENERATE database enrolled until 2016. Sixty-seven patients had to be excluded because of incomplete data in the documentary files. Finally, 320 patients were analyzed for this study: 190 (59%) had abs against NMDAR, 89 (28%) against LGI1, and 41 (13%) against GAD (Table 1). Corroborating previous studies, LGI1+ patients were more often males (55%) than NMDAR+ (24%) and GAD+ (12%) patients (NMDAR+/LGI1+/GAD+ p < 0.001, NMDAR+/LGI1+ p < 0.001, LGI1+/GAD+ p < 0.001). NMDAR+ patients were significantly younger (median: 34 years) at onset than LGI1+ (median: 63 years) and GAD+ patients (median: 50 years; NMDAR+/LGI1+/GAD+, NMDAR+/GAD+, and NMDAR+/GAD+ p < 0.001 respectively). Furthermore, a paraneoplastic condition was moderately frequent in NMDAR+ patients (17%),

---

**Table 1 Demography, Seizure Frequencies, and Seizures as Leading Symptoms**

| Demography and seizure frequency | NMDAR | LGI1 | GAD | NMDAR/GAD/LGI1 | NMDAR/LGI1 | NMDAR/GAD | LGI1/GAD |
|---------------------------------|-------|------|-----|----------------|-------------|-----------|-----------|
| **No. of patients**             | 190   | 89   | 41  | —              | —           | —         | —         |
| **Male**                        | 46 (24%) | 49 (55%) | 5 (12%) | <0.001<sup>a</sup> | <0.001<sup>b</sup> (OR 0.3) | 0.101<sup>b</sup> (OR 8.8) | —         |
| **Tumor**                       | 33 (17%) | 3 (3%)  | 0   | <0.001<sup>a</sup> | <0.001<sup>b</sup> (OR 6.0) | <0.001<sup>b</sup> (OR 1.2) | 0.55<sup>b</sup> |
| **Median age at onset, y (IQR)**| 34 (20.9–45.1) | 63 (53.5–71.0) | 50 (34.1–61.1) | <0.001<sup>c</sup> | <0.001<sup>c</sup> | <0.001<sup>c</sup> | 0.007<sup>c</sup> |
| **Seizures**                    | 113 (59.5%) | 69 (77.5%) | 26 (65.0%) | 0.01<sup>a</sup> | 0.003<sup>b</sup> (OR 0.4) | 0.64<sup>b</sup> | 0.09<sup>b</sup> |
| **Semiology**                   |       |      |     |                |             |           |           |
| **Bilateral tonic-clonic only** | 39/113 (35%) | 15/69 (22%) | 3/26 (12%) | 0.026<sup>c</sup> | 0.094<sup>b</sup> | 0.031<sup>b</sup> (OR 4.0) | 0.381<sup>b</sup> |
| **Focal only**                  | 27/113 (24%) | 33/69 (48%) | 8/26 (31%) | <0.001<sup>b</sup> (OR 0.3) | —           | —         | —         |
| **Both**                        | 40/113 (35%) | 21/69 (30%) | 15/26 (58%) | 0.045<sup>b</sup> | 0.521<sup>b</sup> | 0.046<sup>b</sup> (OR 0.4) | 0.019<sup>b</sup> (OR 0.3) |
| **Seizure as a leading symptom**| 53/190 (28%) | 47/89 (53%) | 20/41 (49%) | <0.001<sup>a</sup> | <0.001<sup>b</sup> (OR 0.3) | 0.015<sup>b</sup> (OR 0.4) | 0.709<sup>b</sup> |

Abbreviations: AE = autoimmune encephalitis; GAD = glutamic acid decarboxylase; LGI1 = leucine-rich glioma-inactivated protein 1; NMDAR = N-methyl-D-aspartate receptor.

<sup>a</sup> The Freeman-Halton test.

<sup>b</sup> The Fisher Exact test.

<sup>c</sup> The Kruskal-Wallis test and Bonferroni correction.
rare in LGI1+ (3%), and absent in GAD+ patients (NMDAR+/LGI1+/GAD+ p < 0.001, NMDAR+/LGI1+ p < 0.001, and NMDAR+/GAD+ p < 0.001).

Proportion of Patients With Seizures

Of importance, seizures were present in almost 2-thirds of patients with ab + AE (N = 208/320; 65%) at the early stage of disease. In detail, 113/190 (60%) patients with NMDAR + AE, 69/89 (78%) patients with LGI1 + AE, and 26/41 (65%) patients with GAD + AE experienced seizures. Seizures occurred less frequently in NMDAR+ than in LGI1+ patients (NMDAR+/LGI1+/GAD+ p = 0.01, NMDAR+/LGI1+ p = 0.003, Table 1). Seizures as a leading symptom to prompt further diagnostics were seen 2.9 times more often in LGI1+ and 2.4 times more often in GAD+ than in NMDAR+ patients (NMDAR+/LGI1+/GAD+ p = 0.01, NMDAR+/LGI1+ p < 0.001, and NMDAR+/GAD+ p = 0.02, Table 1).

When comparing characteristics in the individual ab + AE subgroups for patients with and without seizures, we found that NMDAR+ and GAD+ patients with seizures were younger than those without (NMDAR+ p = 0.003; GAD+ p < 0.001), whereas other demographical characteristics did not differ whether seizures were present or not (for details, see Table 2).

Semiology of Seizures

A detailed description of seizure semiology was available in 51 NMDAR+, 59 LGI1+, and 20 GAD+ patients, which is summarized in Table 3. Knowledge of the specific focal seizure onset was required to apply the ILAE classification guidelines.10

### Table 2 Demographic Data for Patients With ab + AE With and Without Seizures

|                | Sz+ (N)     | Sz− (N)    | Statistical analysis (p value) |
|----------------|-------------|------------|-------------------------------|
| NMDAR (N = 190)| 113 (60%)   | 77 (41%)   | —                             |
| Male           | 25 (22%)    | 21 (27%)   | 0.49a                         |
| Tumor          | 19 (17%)    | 14 (18%)   | 0.85a                         |
| Median age at onset, y (IQR) | 26 (19.0–38.2) | 35 (23.2–49.4) | 0.003b |
| LGI1 (N = 89)  | 69 (78%)    | 20 (23%)   | —                             |
| Male           | 36 (52%)    | 13 (65%)   | 0.44a                         |
| Tumor          | 2 (3%)      | 1 (5%)     | 0.54a                         |
| Median age at onset, y (IQR) | 64 (53.5–70.6) | 69 (53.0–74.5) | 0.28b  |
| GAD (N = 41)   | 26 (63%)    | 15 (37%)   | —                             |
| Male           | 3 (12%)     | 2 (13%)    | 1.0a                          |
| Tumor          | 0           | 0          | —                             |
| Median age at onset, y (IQR) | 37 (31.3–52.9) | 62 (59.1–71.9) | <0.001b |

Abbreviations: ab = antibody; AE = autoimmune encephalitis; GAD = glutamic acid decarboxylase; IQR = interquartile range; LGI1 = leucine-rich glioma-inactivated protein 1; NMDAR = N-methyl-D-aspartate receptor; Sz− = without seizures; Sz+ = with seizures.

a The Fisher exact test.
b The Kruskal-Wallis test and Bonferroni correction.

### Focal Seizures

Whereas focal seizures without impaired awareness were observed similarly often throughout all 3 ab + AE subgroups, focal seizures with impaired awareness were more frequently found in GAD+ patients (17/20, 85%) and in NMDAR+ patients (35/51, 69%) than in LGI1+ patients (28/59, 48%; NMDAR+/LGI1+/GAD+ p = 0.004, NMDAR+/LGI1+ p = 0.03, and LGI1+/GAD+ p = 0.004). FBDS were found solely in 17/59 (29%) of LGI1+ patients (NMDAR/LGI1/GAD p < 0.001).

Motor-onset seizures were most frequently observed in NMDAR+ patients (31/51, 61%) with a broad spectrum of symptoms. Vice versa, in LGI1+ patients, motor-onset seizures were the least often observed among all 3 ab + AE subgroups with 19% of cases (NMDAR+/LGI1+/GAD+ p < 0.001, NMDAR+/LGI1+ p < 0.001, and LGI1+/GAD+ p = 0.009). Of note, FBDS were considered a unique semiology and were separately analyzed. In GAD+ patients, the phenotype of motor-onset seizures was less variable. In this study, automatisms were the key feature being present in all GAD+ patients with motor-onset seizures (NMDAR+/LGI1+/GAD+ p < 0.001, NMDAR+/LGI1+ p = 0.02, and LGI1+/GAD+ p < 0.001); the likelihood of automatism was 4.1 times higher than in NMDAR+ and 10.8 times higher than in LGI1+ patients, whereas other motor signs were scarcely or never reported in GAD+ patients. A clonic motor onset was only seen in NMDAR+ patients (5/51, 10%) (NMDAR+/LGI1+/GAD+ p = 0.02, NMDAR+/LGI1+ p = 0.02, and NMDAR+/GAD+ p = 0.31). Moreover, a myoclonic motor onset was found in NMDAR+ patients in 10/51 (20%) cases,
whereas it was rare in LGI1+ (3/59, 5%) and absent in GAD+ patients (NMDAR+/LGI1+/GAD+ p = 0.02, NMDAR+/LGI1+ p = 0.04, and NMDAR+/GAD+ p = 0.05).

Nonmotor-onset seizures occurred more frequently in GAD+ patients (16/20, 80%) than in one of the other ab + AE subgroups (NMDAR+/LGI1+/GAD+ p ≤ 0.001, NMDAR+/GAD+ p < 0.001, and LGI1+/GAD+ p = 0.02). Whereas ictal autonomic symptoms were found in approximately half of the GAD+ (10/16, 50%) and LGI1+ (10/20, 50%) patients with nonmotor-onset seizures, they were very rare in NMDAR+ (1/51, 2%) patients (NMDAR+/LGI1+/GAD+ p < 0.001, NMDAR+/LGI1+ p < 0.001, and NMDAR+/GAD+ p < 0.001). Notably, pilomotor seizures as a particular subtype of autonomic seizures were reported only in LGI1+ (9/59, 15%) and GAD+ (4/20, 5%) patients. Ictal cognitive symptoms were seldom in LGI1+ patients (5/59, 9%) compared with GAD+ patients (7/20, 35%, p = 0.009).

**Phenomenology of Aura**

In addition, we investigated auras as a key element of seizures that may provide information regarding the seizure onset zone. The detailed analysis of aura is summarized in Table 4. Auras were most prevalent in GAD+ patients (16/20, 80%; NMDAR+/LGI1+/GAD+ p < 0.001), seen 21.5 times more often than in NMDAR+ (8/51, 16%, p < 0.001) and 5.4 times more often than in LGI1+ patients (25/59, 42%, p = 0.004). Déjà vu seemed to serve as a specific aura phenomenon of GAD+ patients (7/20, 35%) compared with that of NMDAR+ (2/51, 2%) and LGI1+ patients (0/59, 0%; NMDAR+/LGI1+/GAD+ p < 0.001, NMDAR+/GAD+ p < 0.001, and LGI1+/GAD+ p < 0.001). An epigastric aura was equally common in LGI1+ (12/59, 20%) and GAD+ (6/20, 30%) patients, but rare in NMDAR+ (1/51, 2%) patients (NMDAR+/LGI1+/GAD+ p < 0.001, NMDAR+/LGI1+ p = 0.003, NMDAR+/GAD+ p = 0.002).

**Bilateral Tonic-Clonic Seizures**

Bilateral tonic-clonic seizures were detected in all ab + AE subgroups (79/130, 61%); they occurred with almost equal frequency in NMDAR+ (38/51, 75%) and in GAD+ (14/20, 70%) patients, while being less common in LGI1+ patients (27/59, 46%) (NMDAR+/LGI1+/GAD+ p = 0.006, NMDAR+/LGI1+ p = 0.003, NMDAR+/GAD+ p = 0.77, and LGI1+/GAD+ p = 0.074, Table 5).

---

**Table 3 Focal Seizures and Their Semiology**

| Focal seizure semiology | Type of AE | NMDAR (n = 51) | LGI1 (n = 59) | GAD 65 (n = 20) | Statistical analysis (p value) |
|-------------------------|------------|---------------|---------------|----------------|--------------------------------|
|                         |            | NMDAR/LGI1+/GAD | NMDAR/LGI1b | NMDAR/GADb | LGI1/GADb |
| Without impaired awareness | 21/51 (41.%) | 34/59 (58%) | 13/20 (65%) | 0.113 | — | — | — |
| With impaired awareness | 35/51 (69%) | 28/59 (48%) | 17/20 (85%) | 0.004 | 0.034 (OR 2.4) | 0.236 | 0.004 (OR 0.2) |
| Motor onset | 31/51 (61%) | 11/59 (19%) | 10/20 (50%) | <0.001 | <0.001 (OR 6.8) | 0.435 | 0.009 (OR 0.2) |
| Automatism | 10/31 (32%) | 5/11 (46%) | 10/10 (100%) | <0.001 | 0.103 | 0.018 (OR 0.2) | <0.001 (OR 0.1) |
| Clonic | 5/31 (10%) | 0/11 (0%) | 0/10 (0%) | 0.022 | 0.019 (OR n.d.) | 0.312 | — |
| Hyperkinetic | 0/31 (0%) | 0/11 (0%) | 1/10 (10%) | 0.154 | 0.282 | 0.253 | — |
| Myoclonic | 10/31 (32%) | 3/11 (27%) | 0/10 (0%) | 0.015 | 0.035 (OR 4.6) | 0.053 | 0.567 |
| Tonic | 6/31 (19%) | 3/11 (27%) | 1/10 (10%) | 0.501 | 0.298 | 0.664 | 1 |
| Nonmotor onset | 15/51 (29%) | 29/59 (49%) | 16/20 (80%) | <0.001 | 0.051 | <0.001 (OR 0.1) | 0.019 (OR 4.1) |
| Autonomic | 1/15 (7%) | 16/29 (55%) | 8/16 (50%) | <0.001 | <0.001 (OR 0.1) | <0.001 (OR 0.03) | 0.399 |
| Behavioral arrest | 0/15 (0%) | 5/29 (17%) | 2/16 (13%) | 0.048 | 0.06 | 0.076 | 1 |
| Cognitive | 9/15 (60%) | 5/29 (17%) | 7/16 (35%) | 0.022 | 0.165 | 0.128 | 0.009 (OR 0.2) |
| Emotional | 1/15 (7%) | 3/29 (10%) | 2/16 (13%) | 0.312 | 0.622 | 0.189 | 0.596 |
| Sensory | 6/15 (40%) | 10/29 (35%) | 6/16 (38%) | 0.188 | 0.589 | 0.084 | 0.216 |
| FBDS | 0/51 (0%) | 17/59 (29%) | 0/20 (0%) | <0.001 | <0.001 (OR n.d.) | — | 0.004 (OR n.d.) |

Abbreviations: AE = autoimmune encephalitis; FBDS = faciobrachial dystonic seizures; GAD = glutamic acid decarboxylase; IQR = interquartile range; LGI1 = leucine-rich glioma-inactivated protein 1; NMDAR = N-methyl-D-aspartate-receptor; OR = odds ratio.

* The Freeman-Halton test.
* The Fisher exact test.
Status Epilepticus

Because the information, whether status epilepticus (SE) occurred, was a mandatory entry in the database, we could analyze all patients with seizures regarding this issue. SE was reported in more than a quarter of NMDAR+ patients with seizures (30/113, 26.5%), whereas it was rare in the other 2 AE subgroups with only 4/69 (6%) LGI1+ and 1/26 (4%) GAD+ patients (NMDAR+/LGI1+/GAD+ p < 0.001, NMDAR+/LGI1+ p < 0.001, NMDAR+/GAD+ p = 0.009).

Thus, NMDAR+ patients had a 5.8 and 9.0 times higher probability to experience SE in comparison with LGI1+ and GAD+, respectively (Table 5).

EEG

EEG data were available in most cases (NMDAR+ 164/190, 86%; LGI1+ 81/89, 91%; GAD+ 32/41, 78%) with pathologic abnormalities in most of the ab + AE patients (NMDAR+ 73%, LGI1+ 68% and GAD+ 75%, p = 0.62). Despite the fact that generalized slowing was found mainly in NMDAR+ patients, all other parameters did not differ in the ab + AE subgroups: generalized slowing in NMDAR + AE patients (48%) has been reported twice as often than in LGI1+ (21%) and 3 times more often than in GAD+ (16%) patients (NMDAR+/LGI1+/GAD+ p < 0.001, NMDAR+/LGI1+ p < 0.001, NMDAR+/GAD+ p < 0.001, eTable 2, links.lww.com/NXI/A747).

We additionally analyzed whether the EEG differed between patients with and without seizures within the ab + AE subgroups (eTable 2, links.lww.com/NXI/A747). In general, EEG was more often pathologic in patients with seizures in the NMDAR+ (p = 0.002) and GAD+ (p = 0.005) subgroups than in the LGI1+ subgroup with seizures in comparison with the subgroup without seizures, respectively. The analysis of epileptiform discharges and ictal patterns was of particular interest. Whereas in NMDAR+ patients, both epileptiform discharges and ictal patterns were not significantly different in patients with and without clinical seizures, epileptiform discharges were observed only in GAD+ patients with clinical seizures (p = 0.029). In LGI1+ and GAD+ patients, ictal patterns were detected only in patients with clinical seizures (LGI1+ 15/63, p = 0.02, GAD+ 6/25, p = 0.3).

Seizures and mRS at Disease Maximum

In general, the mRS was significantly higher in NMDAR+ patients in comparison with LGI1+ and GAD+ patients (Figure 1). In total, 60% of NMDAR+ patients revealed a mRS >4, whereas only 21% GAD+ and 20% LGI1+ patients did (NMDAR+/LGI1+/GAD+ p < 0.001, LGI1+/GAD+ p < 0.001, NMDAR+/GAD+ p < 0.001).

Of note, within the NMDAR+ subgroup, the occurrence of seizures was associated with a 2.8-fold increased risk to show a higher level of disease severity (mRS >4, odds ratio [OR] = 2.800; p < 0.001, Figure 1B). SE in NMDAR+ patients even leads to 5.0-fold increased probability to express an mRS >4 than in NMDAR+ patients without seizures (OR = 5.063; p = 0.001). By contrast, in LGI1+ and GAD+

Table 4 Phenomenology of Aura

| Aura semiology | Type of AE | NMDAR # (n = 51) | LGI1# (n = 59) | GAD 65 (n = 20) | NMDAR/LGI1/GAD | NMDAR/LGI1 | NMDAR/GAD | LGI1/GAD |
|---------------|-----------|-----------------|----------------|---------------|----------------|-------------|------------|----------|
| Aura reported |           | 8 (16%)         | 25 (42%)       | 16 (80%)      | <0.001         | 0.003 (OR 0.3) | <0.001 (OR 0.1) | 0.004 (OR 0.2) |
| Fear         |           | 1 (2%)          | 3 (5%)         | 1 (5%)        | 0.578          | 0.622        | 0.487      | 1        |
| Deja-vu      |           | 2 (4%)          | 0 (0%)         | 7 (35%)       | <0.001         | 0.213        | <0.001 (OR 0.1) | <0.001 (n.d.) |
| Psychic      |           | 1 (2%)          | 3 (5%)         | 2 (10%)       | 0.312          | 0.622        | 0.189      | 0.596    |
| Epigastric   |           | 1 (2%)          | 12 (20%)       | 6 (30%)       | <0.001         | 0.003 (OR 0.1) | 0.002 (OR 0.1) | 0.373    |
| Vegetative (other than epigastric) | | 0 (0%) | 1 (2%) | 1 (5%) | 0.285 | 1 | 0.282 | 0.445 |
| Sensory      |           | 4 (8%)          | 4 (7%)         | 3 (15%)       | 0.523          | 1            | 0.394      | 0.361    |
| Auditory     |           | 0 (0%)          | 0 (0%)         | 1 (5%)        | 0.154          | —            | 0.282      | 0.253    |
| Visual       |           | 0 (0%)          | 0 (0%)         | 1 (5%)        | 0.154          | —            | 0.282      | 0.253    |
| Olfactory    |           | 0 (0%)          | 2 (3%)         | 1 (5%)        | 0.378          | 0.498        | 0.282      | 1        |
| Dizziness    |           | 0 (0%)          | 3 (5%)         | 2 (10%)       | 0.104          | 0.247        | 0.076      | 0.596    |
| Unspecific   |           | 0 (0%)          | 1 (17%)        | 2 (10%)       | 0.062          | 1            | 0.076      | 0.156    |

Abbreviations: AE = autoimmune encephalitis; GAD = glutamic acid decarboxylase; LGI1 = leucine-rich glioma-inactivated protein 1; NMDAR = N-methyl-d-aspartate-receptor; OR = odds ratio.

a The Freeman-Halton test.

b The Fisher exact test.
patients, the occurrence of seizures had no significant effect on the level of disability at disease maximum (Figure 1B).

**Discussion**

Seizures are a common and often leading symptom in early stages of ab + AE. In this study, we provide a large dataset of well-characterized ab + AE patients with documented seizures. In our nationwide multicentric cohort, 2-thirds of all patients with AE positive for the 3 most prevalent abs against NMDAR, LGI1, or GAD presented with seizures at the early stages of disease.

In approximately half of the LGI1+ and GAD+ patients, seizures were the dominating symptom, leading to further diagnostics. NMDAR+ patients were less likely to experience seizures at the early stages compared with the other 2 ab + AE subgroups, and these were indicative for diagnosis only in approximately one-third of cases. If seizures occurred in NMDAR+, they had a significant effect on disease severity, particularly if they evolved into SE.

The occurrence of seizures and their semiology differed throughout the ab + AE subgroups, revealing several characteristic features. Except for the LGI1+ subgroup, patients with seizures were younger than patients without seizures.

According to the more widespread and diffuse cerebral lesion pattern in NMDAR + AE, patients presented with focal and frequent bilateral tonic-clonic seizures. Semiological features of focal seizures in the NMDAR+ subgroup were diverse regarding impaired awareness and motor or nonmotor onset. In motor-onset seizures, clonic and myoclonic features were characteristics for NMDAR+ patients. An aura was uncommon in this ab + AE subgroup compared with that in both LGI1+ and GAD+ patients. On the contrary, bilateral tonic-clonic seizures were typical in NMDAR+ patients, and SE was present in 27% of NMDAR+ cases with seizures, whereas it was a rarity in the 2 other ab + AE subgroups.

In summary, our study points to diverse sites of seizure origins in NMDAR + including the frontal motor zones, which is in line with the findings of Niehusmann et al.11 Thus, our results do not support the common hypothesis that most seizures originate from the temporal lobe in NMDAR+. Extrapyramidal movements are very common in NMDAR+ patients, particularly orofacial dyskinesia, which might be mistaken for temporal seizure symptoms.13 In general, the differentiation between epileptic seizures and extrapyramidal movements within the NMDAR+ population is challenging. Studies with continuous video-EEG monitoring are required to further investigate and clarify these aspects. Similarly, a more frequent application of video-EEG monitoring would also help to determine more precisely the incidence of SE in NMDAR + AE. In our study, the proportion of SE was highest in NMDAR+ patients with 27%. These data should be interpreted with caution because we were not able to explicitly reanalyze the EEG data from each center. A previous study revealed that in NMDAR+ AE, abnormal EEG findings such as rhythmic delta activity, movement disorders, and impaired awareness are frequently misinterpreted as SE.14 In a recent systemic review dealing with EEG abnormalities and seizures in AE, “SE on EEG” was even found in only 0.2% of NMDAR+ patients.15 Considering the diagnostic difficulties mentioned earlier, this result should be also viewed with caution because the classification, whether SE was present or not, thus considerably depended largely on the epileptological expertise of the reporting physician.

In our LGI1+ population, a significant proportion of patients experienced only focal seizures (48%). Thereby, focal seizures with and without impaired awareness occurred with a similar prevalence. The more detailed analysis revealed that nonmotor-seizure onset with autonomic features was the most typical semiology in LGI1+ patients. An aura was reported in 42% of cases, in half of them as an epigastric aura, suggesting a temporal origin. As a peculiar symptom, we observed pilomotor seizures in 15% of the LGI1+ patients, which also indicates involvement of the limbic structures. In
line with these findings, previous smaller case series also reported seizures with temporal semiology with autonomic symptoms and impaired awareness as main seizure type in LGI1 + AE. The frequency of FBDS in our LGI1+ cohort was 28%, and their occurrence was unique in the LGI1+ subgroup. Hence, our study adds further evidence to the assumption that FBDS can be nearly considered as pathognomonic for LGI1 + AE and are not detected in other forms of AE. We included patients from 2006 to 2016, and the awareness of FBDS has just started since their first description in 2011. Hence, FBDS might be missed in early LGI1 patients before 2011. In previous case studies and smaller patient series, the frequency of FBDS in LGI1 were 32%, 48%, and 69%.

GAD+ patients presented with both focal and bilateral tonic-clonic seizures. Focal seizures occurred predominantly with impaired awareness, with motor onset or nonmotor onset. Typical features were automatisms in motor-onset seizures. Regarding aura phenomenon, déjà vu was nearly specific for GAD+ patients. The epigastric aura was the second most common aura phenomenon. Altogether, seizure semiology in GAD+ patients is characteristic for a temporal seizure origin. SE was very rare in this ab + subgroup. A comprehensive analysis of seizure semiology in GAD+ patients is lacking so far. In previous studies of GAD + AE, descriptions of seizure semiology mainly simplified to terms such as "localization-related seizures, temporal lobe seizures, or seizures with temporal semiology."

(A) Shows the distribution of scores of all patients in the 3 subgroups of ab + AE. mRS was significantly higher in NMDAR+ patients in comparison with that in LGI1+ (mRS >4, OR = 11.2, p < 0.001) and GAD+ patients (mRS >4, OR = 6.2, p < 0.001). (B) Shows the scores in patients with and without seizures within the individual ab + subgroups. In the NMDAR+ subgroup, the occurrence of seizures was associated with a 2.8-fold increased risk to show a higher level of disease severity (mRS >4, OR = 2.800; p < 0.001), whereas it had no significant effect in LGI1+ and GAD+ patients. GAD = glutamic acid decarboxylase; LGI1 = leucine-rich glioma-inactivated protein 1; NMDAR = N-methyl-D-aspartate receptor.

Figure 1 Scores of the Modified Rankin Scale (mRS) at Disease Maximum in the Acute Stage
Nevertheless, the occurrence of musicogenic reflex seizures in GAD+ patients is in line with a predominant temporal seizure onset in this ab + AE subgroup. Besides the clinical constellation of intractable temporal lobe seizures, a second scenario with acute onset and SE has been described in GAD + AE. In this study, we detected only 1 patient with SE; thus, SE may rather be a rare clinical manifestation in GAD + AE.

Despite the wide use of EEG in ab + AE in clinical practice, there exist only few systematic data on that subject regarding sensitivity and specificity of pathologic findings, especially in assessing the risk of seizures. The best knowledge exists for pathologic EEG findings in NMDAR + AE with diffuse and focal slowing as most relevant findings. In a recent study focusing on the predictive value of EEG recordings in NMDAR+ adult and children patients, 96% of adults and all children had abnormal findings at their first EEG recording, pointing to a high sensitivity. Furthermore, an abnormal posterior EEG rhythm at onset was considered to have a negative predictive value for clinical outcome. In studies with LGI1+ patients, approximately 25% of patients showed focal slowing and approximately 30% of patients had epileptiform discharges. We are not aware of a larger cohort of GAD+ patients exploring systemic EEG data. There are only a few cases in heterogenic ab + AE patient cohorts reporting EEG findings, revealing mainly focal interictal discharges.

In our cohort, we could confirm previous findings that focal and generalized slowing are the most prevalent EEG findings. Generalized slowing was present in nearly half of the NMDAR+ patients but only in 21% of LGI1+ and 16% of GAD+ patients, once again reflecting the more diffuse distribution in NMDAR + AE. Of interest, NMDAR+ patients had both epileptiform discharges and ictal patterns irrespective of clinical seizure occurrence, whereas ictal patterns in LGI1+ and GAD+ patients were only detected in patients with clinical seizures. However, we found no significant relevance of EEG to predict the risk of having seizures in the early stage of disease.

Our study has several limitations. First, we included only patients from the GENERATE database, which is a free alliance of hospitals with different medical care standards throughout Germany. Thus, the study may bear a relevant risk for a selection bias. Indeed, such a selection bias can be assumed in many if not almost all other reports on the topic of ab + AE. To our knowledge, only the group of Titulaer from Rotterdam, the Netherlands, reported country-wide epidemiologic data of ab + AE because they serve as the only national reference ab laboratory in Netherlands. All other reports share the problem of data retrieved from specialized reference laboratory databases or from single specialized centers. With the GENERATE cohort, we aim to overcome the limitations of small monocentric studies or studies of some specialized centers. The nationwide approach widens the spectrum of patients reported not only from specialized tertiary but also from other medical care standard centers involved in the treatment of AE patients (generate-net.de). A further argument against relevant selection bias in our population is the matching demographical distribution with previous reports of the distinct ab + AE subgroups. NMDAR+ patients are mainly females of middle or younger age with a tumor rate of approximately 20%. LGI1+ patients are predominantly older males with rare tumor association, and finally, GAD+ patients are mainly middle-aged women without tumor association. Second, the data quality in a multicentric registry study has to be critically questioned. Indeed, there could be a relevant information gap because we were not able to reevaluate in person all data included in the database. Instead, we asked the collaborating centers to provide anonymized full and detailed descriptions of seizure semantics and EEG recordings. We therefore cannot exclude some missing details according to the level of epileptological expertise in the different sites. Third, our aim was to assess seizure characteristics in the early stage of ab-associated AE. The distinction between acute symptomatic seizures due to an active encephalitis and autoimmune-associated epilepsy as a chronic disease, as conceptualized by Geis et al., was behind the scope of our study and will be addressed in future investigations. After a subset of patients with coexisting NMDAR and myelin oligodendrocyte glycoprotein abs was first reported in 2014, this topic has gained increasing interest. However, the clinical relevance of these coexisting antibodies remains controversial at present. Because these findings were largely unknown during patient recruitment in this study, we cannot report any further results regarding this.

Seizures are a frequent and important clinical symptom in the early stages of ab + AE with abs against NMDAR, LGI1, and GAD with relevant effect on diagnosis and disease severity. Patients with NMDAR + AE had only few characteristic semiological features according to the more diffuse cerebral affection, but developing seizures is associated with a more severe disease course. By contrast, semiology in LGI1+ and GAD+ patients clearly pointed to a more focal and temporal seizure onset. FBDS are pathognomonic for LGI1+AE. SE seems to be more frequent for NMDAR + AE.

Acknowledgment
The authors are indebted to all members of the GENERATE e.V. (generate-net.de) and all patients and their relatives for supporting this study. Particularly The authors would like to thank Dr. Thomas Lehmann (Institute of Medical Statistics and Computer Science, University Hospital Jena, Germany) for support with the statistical analysis.

Study Funding
The authors report no targeted funding.

Disclosure
T. Kaaden, M. Madlener, and K. Angstwurm report no disclosures relevant to the manuscript; C.G. Bien receives research support from the Deutsche Forschungsgemeinschaft
(German Research Council, Bonn, Germany) and Gerd-Altenhof-Stiftung (Deutsches Stiftungs-Zentrum, Essen, Germany); Y. Bogarin, K. Doppler, A. Finke, S. T. Gerner, G. Reimann, M. Häusler, R. Handreka, K. Hellwig, and M. Kaufmann report no disclosures relevant to the manuscript; C. Kellinghaus received speakers honoraria from Eisai, UCB Pharma, GW Pharma, Marinus, Angelini Pharma, Zogenix; he served in advisory boards for UCB Pharma, Eisai, GW Pharma; P. Koertvleesey, A. Kraft, J. Lewerenz, T. Menge, and A. Paliantonis report no disclosures relevant to the manuscript; F. von Powedils reports industry-funded travel with the support of Desitin Arzneimittel GmbH (Hamburg, Germany), Bial (Mörfelden-Walldorf, Germany), Eisai Pharma (Frankfurt, Germany), Arvelle Therapeutics/Angelinpharma (München, Germany), GW Pharmaceuticals companies (München, Germany), and UCB Pharma (Monheim, Germany), honoraria obtained for speaking engagements from Desitin Arzneimittel GmbH (Hamburg, Germany), Zogenix (München, Germany), Bial (Mörfelden-Walldorf, Germany), Arvelle Therapeutics/Angelinpharma (München, Germany), GW Pharmaceuticals companies (München, Germany), and UCB Pharma (Monheim, Germany), and as part of a speaker’s bureau for Bial (Mörfelden-Walldorf, Germany), Eisai Pharma (Frankfurt, Germany), Arvelle Therapeutics/Angelinpharma (München, Germany), GW Pharmaceuticals companies (München, Germany), and UCB Pharma (Monheim, Germany); H. Prüss, S. Rauer, M. Ringelstein, K. Rostásy, I. Schirotzek, J. Schwabe, P. Sokolowski, and M. Suess report no disclosures relevant to the manuscript; K.-W. Sühs obtained honoraria for speaking engagements and consultancy from Merck, Biogen, and Bristol-Myers Squibb; R. Surges has received fees as speaker or consultant from Angelini, Arvelle, Bial, Desitin, Eisai, LivaNova, Novartis, UCB Pharma, and UnEEG; S. C. Tauber, F. Thaler, F. Then Bergh, C. Urbanek, K.-P. Wandinger, B. Wildemann, S. Mues, U. Zettl, F. Leypoldt, N. Melzer, and C. Geis report no disclosures relevant to the manuscript; M. P. Malter obtained honoraria for speaking engagements and consultancy from Merck, Biogen, and UCB; R. Malter obtained honoraria for speaking engagements and consultancy from UCB (Monheim, Germany) and EISAI (Frankfurt, Germany); A. Kunze reports no disclosures relevant to the manuscript. Go to Neurology.org/NN for full disclosure.

**Publication History**

Received by Neurology: Neuroimmunology & Neuroinflammation February 2, 2022. Accepted in final form August 8, 2022. Submitted and externally peer reviewed. The handling editor was Joseph O. Dalmau, MD, PhD, FAAN.

**Appendix** (continued)

| Name                | Location                                      | Contribution                                      |
|---------------------|-----------------------------------------------|--------------------------------------------------|
| Marie Madiener, MD  | University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Neurology | Major role in the acquisition of data |
| Klemens Angstwurm, MD | Department of Neurology, University of Regensburg | Major role in the acquisition of data |
| Christian G Blien, MD | Department of Epileptology (Krankenhaus Mara), Bielefeld University, Medical School, Campus Bielefeld-Bethel | Major role in the acquisition of data |
| Yuri Bogarin, MD    | Department of Psychiatry and Psychotherapy, Asklepios Hospital Teupitz | Major role in the acquisition of data |
| Kathrin Doppler, MD  | Department of Neurology, University of Würzburg | Major role in the acquisition of data |
| Alexander Finke, MD | Department of Neurology, Hospital Lüneburg | Major role in the acquisition of data |
| Stefan T Gerner, MD | Department of Neurology, University Hospital Erlangen | Major role in the acquisition of data |
| Gernot Reimann, MD  | Department of Neurology, Klinikum Dortmund | Major role in the acquisition of data |
| Martin Hauser, MD   | Department of Neurology, RWTH University Hospital Aachen | Major role in the acquisition of data |
| Robert Handreka, MD | Department of Neurology, Carl-Thiem Klinikum Cottbus | Major role in the acquisition of data |
| Kerstin Hellwig, MD | Department of Neurology, University of Bochum | Major role in the acquisition of data |
| Max Kaufmann, MD    | Institut für Neuroimmunologie und Multiple Sklerose, Zentrum für Molekulare Neurobiologie Hamburg, Universitätshospital Hamburg-Eppendorf, Hamburg, Germany | Major role in the acquisition of data |
| Christoph Kellinghaus, MD | Department of Neurology, Klinikum Osnabrück | Major role in the acquisition of data |
| Peter Koertvleesey, MD | Department of Neurology, University of Magdeburg | Major role in the acquisition of data |
| Andrea Kraft, MD    | Department of Neurology, Martha-Maria Hospital Halle | Major role in the acquisition of data |
| Jan Lewerenz, MD    | Department of Neurology, University of Ulm | Major role in the acquisition of data |
| Til Menge, MD       | Department of Neurology, Center for Neurology and Neuropsychiatry, LVR-Klinikum, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany | Major role in the acquisition of data |
### Appendix (continued)

| Name                          | Location                                                                 | Contribution                                           |
|-------------------------------|--------------------------------------------------------------------------|--------------------------------------------------------|
| Asterios Paliantonis, MD       | Department of Neurology, Klinikum Hirslanden, Zürich                     | Major role in the acquisition of data                  |
| Felix von Podewils, MD         | Department of Neurology, University of Greifswald                         | Major role in the acquisition of data                  |
| Harald Prüss, MD               | Department of Neurology and Experimental Neurology, Charité Berlin, and German Center for Neurodegenerative Diseases (DZNE) Berlin | Major role in the acquisition of data                  |
| Sebastian Rauer, MD            | Department of Neurology, University of Freiburg                           | Major role in the acquisition of data                  |
| Marius Ringelstein, MD         | Department of Neurology, Center for Neurology and Neuropsychiatry, LVR-Klinikum, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany; Department of Neurology, Medical Faculty, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany | Major role in the acquisition of data                  |
| Kevin Rostágy, MD              | Department of Neuropediatrics, Vestsche Kinder-und Jugendklinik Datteln   | Major role in the acquisition of data                  |
| Ingo Schirotzek, MD            | Department of Neurology, University Hospital Giessen and Marburg, Giessen | Major role in the acquisition of data                  |
| Julia Schwabe, MD              | Department of Neurology, Asklepios Hospital Nord, Hamburg                 | Major role in the acquisition of data                  |
| Piotr Sokolowski, MD           | Department of Neurology, Hospital Hubertusburg, Wermsdorf                 | Major role in the acquisition of data                  |
| Marie Suesse, MD               | Department of Neurology, University of Greifswald                         | Major role in the acquisition of data                  |
| Kurt-Wolfram Sühs, MD          | Department of Neurology, University Hospital Hannover                      | Major role in the acquisition of data                  |
| Rainer Surges, MD              | Department of Epileptology, University Hospital Bonn                      | Major role in the acquisition of data                  |
| Simone C Tauber, MD            | Department of Neurology, RWTH University Hospital Aachen                  | Major role in the acquisition of data                  |
| Franziska Thaler, MD           | Institute of Clinical Neuroimmunology, University Hospital, Ludwig-Maximilians-Universität Munich, Munich, Germany and Biomedical Center (BMC), Medical Faculty, Ludwig-Maximilians-Universität Munich, Martinsried, Germany | Major role in the acquisition of data                  |
| Florian Then Bergh, MD         | Department of Neurology, University of Leipzig, Leipzig                    | Major role in the acquisition of data                  |
| Christian Urbanek, MD          | Department of Neurology, Hospital Ludwigshafen                             | Major role in the acquisition of data                  |
| Klaus-P. Wандinger, MD         | Institute of Clinical Chemistry, University Hospital Schleswig-Holstein, Kiel/Lübeck, Germany | Major role in the acquisition of data                  |
| Brigitte Wildemann, MD         | Department of Neurology, University of Heidelberg                          | Major role in the acquisition of data                  |
| Sigrid Mues, MD                | Department of Neurology, University Hospital Rostock                        | Major role in the acquisition of data                  |
| Frank Leypoldt, MD             | Department of Neurology, Christian-Albrechts-University Kiel                | Major role in the acquisition of data                  |
| Nico Melzer, MD                | Department of Neurology, University of Freiburg; Department of Neurology with Institute of Translational Neurology, University Hospital Muenster | Major role in the acquisition of data                  |
| Christian Geis, MD             | Hans-Berger Department of Neurology, University Hospital Jena              | Major role in the acquisition of data                  |
| Michael Malter, MD             | University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Neurology | Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data; study concept or design |
| Albrecht Kunze, MD             | Hans-Berger Department of Neurology, University Hospital Jena; Department of Neurology, Zentraalklinik Bad Berka, Germany | Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data; study concept or design |

### References

1. Geis C, Planaguma J, Carreño M, Graus F, Dalmau J. Autoimmune seizures and epilepsy. J Clin Invest. 2019;129(3):926-940.
2. Graus F, Tintulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15(4):391-404.
3. Irani SR, Michell AW, Lang B, et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol. 2011;69(5):892-900.
4. Liimatainen S, Peltola M, Sabater L, et al. Clinical significance of glutamic acid decarboxylase antibodies in patients with epilepsy. Epilepsia. 2010;51(5):760-767.
5. Viciu S, Desestret V, Dzavy F, et al. Clinical specificity of adult male patients with NMDA receptor antibodies encephalitis. Neurology. 2014;82(7):556-563.
6. Dalmau J, Geis C, Graus F. Autoantibodies to synaptic receptors and neuronal cell surface proteins in autoimmune diseases of the central nervous system. Physiol Rev. 2017;97(2):839-887.
7. Irani SR, Stagg CJ, Schott JM, et al. Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype. Brain. 2013;136(pt 10):3151-3162.

8. Thompson J, Bi M, Murchison AG, et al. Faciobrachial Dystonic Seizures Study Group. The importance of early immunotherapy in patients with faciobrachial dystonic seizures. Brain. 2018;141(2):348-356.

9. Malter MP, Helmstaedter C, Urbach H, Vincent A, Bien CG. Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Ann Neurol. 2010;67(4):470-478.

10. Fisher RS, Cross JL, French JA, et al. Operational classification of seizure types by the international League against epilepsy: position paper of the ILAE commission for classification and terminology. Epilepsia. 2017;58(4):S22-S30.

11. Niehusmann P, Dalmau J, Rudlowski C, et al. Diagnostic value of N-methyl-D-aspartate receptor antibodies in women with new-onset epilepsy. Arch Neurol. 2009;66(4):458-464.

12. Vogrig A, Joubert B, Andre-Obadia N, Gigli GL, Rheims S, Honnorat J. Seizure specificities in patients with antibody-mediated autoimmune encephalitis. Epilepsia. 2019;60(8):1508-1525.

13. Dalmau J, Gleicher AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7(12):1091-1098.

14. Jeannin-Mayer S, Andre-Obadia N, Rosenberg S, et al. EEG analysis in anti-NMDA receptor encephalitis: description of typical patterns. Clin Neurophysiol. 2019;130(2):289-296.

15. Yesokumar AK, Coughlan A, Fastman J, et al. Seizures in autoimmune encephalitis-A systematic review and quantitative synthesis. Epilepsia. 2021;62(2):397-407.

16. Navarro V, Kas A, Aparisi E, et al. Collaborators. Motor cortex and hippocampus are the two main cortical targets in LGI1-antibody encephalitis. Brain. 2016;139(pt 4):1079-1093.

17. van Sonderen AV, Arends S, Tavy DJ, et al. Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABABR encephalitis. Neurol. 2019;92(19):e2185-e2196.

18. de Bruijn MAAM, van Sonderen A, van Coevorden-Hameete MH, et al. Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABABR encephalitis. Neurology. 2019;92(19):e2185-e2196.

19. Daif A, Lukas RV, Issa NP, et al. Antigliutamic acid decarboxylase 65 (GAD65) antibody-associated epilepsy. Epilepsy Behav. 2018;80:331-336.

20. Falip M, Rodriguez-Bel I, Castaner S, et al. Hippocampus and insula are targets in epileptic patients with glutamic acid decarboxylase antibodies. Front Neurol. 2018;9:1143.

21. Peltola J, Kulmala P, Isojärvi J, et al. Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsy. Neurology. 2000;55(1):46-50.

22. Falip M, Rodrigues-Bel I, Castaner S, et al. Musicogenic reflex seizures in epilepsy with glutamic acid decarboxylase antibodies. Acta Neurol Scand. 2018;137(2):272-276.

23. Jesus-Ribeiro J, Bozorgi A, Alkhaldi M, Shaqebeh M, Fernandez-Baca Vaca G, Katriji B. Autoimmune musicogenic epilepsy associated with anti-glutamic acid decarboxylase antibodies and stiff-person syndrome. Clin Case Rep. 2020;8(1):61-64.

24. Smith KM, Zaleski NL, Budhram A, et al. Musicogenic epilepsy: expanding the spectrum of glutamic acid decarboxylase 65 neurological autoimmunity. Epilepsia. 2021;62(5):e76-e81.

25. Khawaja AM, Vines BL, Miller DW, Szaflarski JP, Amara AW. Refractory status epilepticus and glutamic acid decarboxylase antibodies in adults: presentation, treatment and outcomes. Epileptic Disord. 2016;18(1):34-43.

26. Kanter IC, Huttner HB, Staykov D, et al. Cyclophosphamide for anti-GAD antibody-positive refractory status epilepticus. Epilepsia. 2008;49(5):914-920.

27. Sonderen AV, Arends S, Tavy DJ, et al. Predictive value of electroencephalography in anti-NMDA receptor encephalitis. J Neurol Neurosurg Psychiatry. 2018;89(10):1101-1106.

28. Gadoth A, Pittcock SJ, Dubey D, et al. Expanded phenotypes and outcomes among 256 LGI1/CASPR2-IgG-positive patients. Ann Neurol. 2017;82(1):79-92.

29. Baysal-Kirac L, Tuzun E, Altindag E, et al. Are there any specific EEG findings in autoimmune epilepsies? Clin EEG Neurosci. 2016;47(3):224-234.

30. Quek AML, Britton JW, McKeon A, et al. Autoimmune epilepsy: clinical characteristics and response to immunotherapy. Arch Neurol. 2012;69(5):582-593.

31. Vigena AM, Bialow RS, Oke C, et al. Routine diagnostics for neural antibodies, clinical correlates, treatment and functional outcome. J Neuro. 2020;267(7):2101-2114.

32. Titulaer MJ, Höfterger R, Iruka T, et al. Overlapping demyelinating syndromes and anti-N-methyl-D-aspartate receptor encephalitis. Ann Neurol. 2014;75(3):411-428.

33. Ding J, Li X, Tian Z. Clinical features of coexisting anti-NMDAR and MOG antibody-associated encephalitis: a systematic review and meta-analysis. Front Neurol. 2021;12:711376.
Seizure Semiology in Antibody-Associated Autoimmune Encephalitis
Tillman Kaaden, Marie Madlener, Klemens Angstwurm, et al.

Neurol Neuroimmunol Neuroinflamm 2022;9;
DOI 10.1212/NXI.0000000000200034

This information is current as of October 20, 2022

Updated Information & Services
including high resolution figures, can be found at:
http://nn.neurology.org/content/9/6/e200034.full.html

References
This article cites 33 articles, 1 of which you can access for free at:
http://nn.neurology.org/content/9/6/e200034.full.html##ref-list-1

Citations
This article has been cited by 1 HighWire-hosted articles:
http://nn.neurology.org/content/9/6/e200034.full.html##otherarticles

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://nn.neurology.org/misc/about.xhtml#permissions

Reprints
Information about ordering reprints can be found online:
http://nn.neurology.org/misc/addir.xhtml#reprintsus